L1PA.F LEE S PHARMACEUTIC.HD-05
- Market cap
- EUR 69.7M
- P/E
- 5.6x
- P/B
- 0.28x
- ROE
- 4.5%
- Dividend yield
- 6.98%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is L1PA.F undervalued?
Graham numberThe Graham number of LEE S PHARMACEUTIC.HD-05 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LEE S PHARMACEUTIC.HD-05 fundamental analysis
No fundamental analysis for LEE S PHARMACEUTIC.HD-05 yet.
LEE S PHARMACEUTIC.HD-05 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LEE S PHARMACEUTIC.HD-05
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment man…
Full company profileLEE S PHARMACEUTIC.HD-05 financial statements
LEE S PHARMACEUTIC.HD-05 annual financial statements (HKD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.27B | 1.23B | 1.05B | 1.40B | 1.44B |
| Gross Profit | 806M | 771M | 551M | 753M | 730M |
| Operating Income | -173M | 76.5M | -7.36M | 77.4M | 75.8M |
| EBITDA | - | 227M | 192M | 260M | 239M |
| Net Income | 1.99B | 51.3M | 16.7M | 93.1M | 91.9M |
| EPS | 3.37 | 0.09 | 0.03 | 0.16 | 0.16 |
| Balance Sheet | |||||
| Total Assets | 3.64B | 2.78B | 2.89B | 2.62B | 3.46B |
| Total Liabilities | 1.25B | 940M | 930M | 1.07B | 1.56B |
| Shareholders' Equity | 2.46B | 1.92B | 2.04B | 1.65B | 2.05B |
| Cash & Short-term Investments | 278M | 189M | 171M | 217M | 350M |
| Cash Flow | |||||
| Operating Cash Flow | 211M | 284M | 110M | 242M | 333M |
| Capital Expenditure | 371M | 214M | 160M | 208M | 232M |
| Free Cash Flow | -160M | 69.8M | -49.6M | 34.5M | 101M |
| Ratios | |||||
| ROE | 80.6% | 2.7% | 0.8% | 5.6% | 4.5% |
| ROA | 54.6% | 1.8% | 0.6% | 3.6% | 2.7% |
| Net Profit Margin | 156.9% | 4.2% | 1.6% | 6.7% | 6.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LEE S PHARMACEUTIC.HD-05 dividends
- Dividend yield
- 6.98%
- Forward dividend
- 0.01 EUR
- Payout ratio
- 30.1%
- Ex-dividend date
- Sep 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | HKD 27.7M | 0.05 | 30.1% |
| 2024 | HKD 17.7M | 0.03 | 19.0% |
| 2023 | HKD 10.6M | 0.02 | 63.5% |
| 2022 | HKD 24.1M | 0.04 | 47.1% |
| 2021 | HKD 35.9M | 0.06 | 1.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LEE S PHARMACEUTIC.HD-05
- Insiders 49.30%
- Institutions 6.95%
- Public & others 43.75%
- Shares outstanding 589M
- Free float 247M
LEE S PHARMACEUTIC.HD-05 company profile
- Company name
- LEE S PHARMACEUTIC.HD-05
- Ticker
- L1PA.F
- ISIN
- KYG5438W1116
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,137
- Fiscal year end
- December
- Address
- Building 20E, Sha Tin, Hong Kong
- Phone
- 852 2314 1282
- Website
- leespharm.com
About LEE S PHARMACEUTIC.HD-05
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
LEE S PHARMACEUTIC.HD-05 management
9- Ms. Siu Fong LeeChairman & Compliance Officer · born 1957
- Dr. Xiaoyi Li Ph.D.Founder, Senior Adviser & Non-Executive Director · born 1963
- Ms. Wanee LeelalertsuphakunMD, Chief Marketing & Sales Officer and Executive Director · born 1954
- Mr. Yiu Ming ChowGroup CFO & Company Secretary · born 1973
- Ms. Ling FangCorporate Culture and Public Relations Director · born 1969
- Mr. Yueshen ChenDirector of Administration in China · born 1959
- Mr. Tsui Victor Kailok M.Sc., P.E.Group Chief Manufacturing Officer · born 1967
- Mr. Yuanjue SunChief Medical Officer
- Mr. Zhongyu JiaoGroup Deputy GM & GM of the Risk Control Centre · born 1970